Try our beta test site

Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01682512
First received: August 10, 2012
Last updated: March 2, 2017
Last verified: March 2017
  Purpose
The primary objectives of this trial are (1) To show PK (Pharmacokinetic) similarity of BI 695500 to rituximab. (2)To establish statistical equivalence of efficacy of BI 695500 and rituximab, in patients with moderately to severely active RA (Rheumatoid Arthritis), based on the change in Disease Activity Score 28 (DAS28) score measured at 24 weeks compared to Baseline and the American College of Rheumatology 20% (ACR20) response rate at Week 24.

Condition Intervention Phase
Arthritis, Rheumatoid
Drug: BI 695500
Drug: rituximab
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (masked roles unspecified)
Primary Purpose: Treatment
Official Title: Efficacy, Pharmacokinetics, and Safety of BI 695500 Versus Rituximab in Patients With Moderately to Severely Active Rheumatoid Arthritis: a Randomized, Double-blind, Parallel Arm, Multiple Dose, Active Comparator Trial.

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Change from Baseline in DAS28-ESR (Disease Activity Score 28-erythrocyte sedimentation rate) [ Time Frame: WEEK 24 ]
  • PK (Part I only): AUC0-inf pred (area under the plasma concentration versus time curve from time zero to infinity, over both dosages [ Time Frame: WEEK 16 ]
  • PK (Part I only): AUC0-336 (area under the plasma concentration versus time curve from time zero to 336 hours) [ Time Frame: WEEK 16 ]
  • PK (Part I only): observed Cmax (maximum plasma concentration, determined after the second drug infusion) [ Time Frame: WEEK 16 ]
  • PK (Part I only): AUC0-tz (area under the plasma concentration versus time curve from time zero to the last measurable concentration, (determined over both dosages) [ Time Frame: WEEK 16 ]

Secondary Outcome Measures:
  • PK (Part I only): AUC0-inf, ppk, determined over both dosages [ Time Frame: WEEK 16 ]
  • The proportion of patients meeting the ACR20 (American College of Rheumatology 20% response criteria) [ Time Frame: WEEK 24 ]

Enrollment: 237
Study Start Date: September 2012
Study Completion Date: October 2016
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Part I BI 695500 group
BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
Drug: BI 695500
Active Comparator: Part I rituximab group 1
rituximab, Two infusions separated by 2 weeks, Intravenous infusion
Drug: rituximab
Active Comparator: Part I rituximab group 2
rituximab, Two infusions separated by 2 weeks, Intravenous infusion
Drug: rituximab
Experimental: Part II BI 695500 group
BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
Drug: BI 695500
Active Comparator: Part II rituximab group
rituximab, Two infusions separated by 2 weeks, Intravenous infusion
Drug: rituximab

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Must give written informed consent and be willing to follow the protocol.
  2. Male or female participants, between 18 and 80 years of age, who have a diagnosis of moderately to severely active RA for at least 6 months as defined by at least six swollen joints (66 joint count) and at least eight tender joints (68 joint count) at Screening and Baseline (Day 1), and either an erythrocyte sedimentation rate (ESR) of > 28 mm/hour OR a CRP level > 1.0 mg/dL (normal: < 0.4 mg/dL) at Screening. Patients must have had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor.
  3. Positive for RF and/or anti-CCP antibodies.
  4. Current treatment for RA on an outpatient basis:

    1. Must be currently receiving and tolerating oral or parenteral MTX therapy at a dose of 15-25 mg per week (dose may be as low as 10 mg per week if the patient is unable to tolerate a higher dose) for at least 12 weeks immediately prior to Day 1. The dose should be stable for at least 4 weeks prior to Day 1 until Week 24. After Week 24 the administration route can be changed at the investigator's discretion.
    2. Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or equivalent during the entire study (mandatory co-medication for MTX treatment).
    3. Biologic agents and DMARDs (other than MTX) must be withdrawn at least 2 weeks prior to Day 1, except azathioprine and etanercept which must be withdrawn at least 4 weeks prior to Day 1; abatacept, adalimumab, anakinra, certolizumab, infliximab, and golimumab at least 8 weeks prior to Day 1; tocilizumab at least 10 weeks prior to Day 1.
    4. Leflunomide must be withdrawn at least 8 weeks prior to Day 1 or a minimum of 2 weeks prior to Day 1 if after 11 days of standard cholestyramine washout.
    5. If receiving current treatment with oral corticosteroids (other than intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain stable.
    6. Intra-articular and parenteral corticosteroids are not permitted within 6 weeks prior to Baseline Day 1 or throughout the trial, with the exception of IV administration of 100 mg methylprednisolone 30 to 60 minutes prior to each infusion as this is part of the trial procedures.
    7. Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day 1.
    8. Patients may be taking oral hydroxychloroquine provided that the dose is not greater than 400 mg/day or chloroquine provided that the dose is not greater than 250 mg/day. These doses must have been stable for a minimum of 12 weeks prior to Day 1. The hydroxychloroquine or chloroquine treatment will need to be continued at a stable dose with the same formulation until the end of the trial.
  5. For participants of reproductive potential (males and females), use of a reliable means of contraception (e.g., hormonal contraceptive, patch, intrauterine device, physical barrier) has to be used throughout trial participation. Females of child-bearing potential must also agree to use an acceptable method of contraception for 12 months following completion or discontinuation from the trial.

Exclusion criteria:

  1. ACR functional Class IV or wheelchair/bed bound.
  2. Primary or secondary immunodeficiency (history of, or currently active), including known history of human immunodeficiency virus infection.
  3. History of positive purified protein derivative test (positive tuberculosis [TB] test) without treatment for TB infection or chemoprophylaxis for TB exposure.
  4. Positive HIV or TB at screening.
  5. Known coronary artery disease or significant cardiac arrhythmias or severe congestive heart failure (New York Heart Association classes III or IV), or interstitial lung disease observed on chest X-ray.
  6. History of IgE-mediated or non-IgE-mediated hypersensitivity or known anaphylaxis to mouse proteins or a history of hypersensitivity to antibody therapy.
  7. History of cancer including solid tumors, hematologic malignancies, and carcinoma in situ (except participants with previous resected and cured basal or squamous cell carcinoma, treated cervical dysplasia, or treated in situ Grade I cervical cancer within 5 years prior to the Screening Visit).
  8. History of pancreatitis or current peptic ulcer disease.
  9. Receipt of a live/attenuated vaccine within 12 weeks prior to the Screening Visit.
  10. Any condition or treatment (including biologic therapies) that, in the opinion of the investigator, may place the patient at unacceptable risk during the trial.
  11. Pregnancy or breast feeding.
  12. History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, pulmonary fibrosis, or Feltys syndrome, scleroderma, inflammatory myopathy, mixed connective tissue disease, or any overlap syndrome).
  13. Diagnosis of juvenile idiopathic arthritis, also known as juvenile RA, and/or RA before age 16.
  14. Any surgical procedure, including bone/joint surgery/synovectomy (including joint fusion or replacement) within 12 weeks prior to the Screening Visit or planned within 24 weeks of the Screening Visit.
  15. Lack of peripheral venous access.
  16. Evidence of significant uncontrolled concomitant disease such as, but not limited to, nervous system, renal, hepatic, endocrine, or gastrointestinal disorders which, in the investigator's opinion, would preclude patient participation.
  17. Known concurrent viral hepatitis or known positivity to HBe-ag, HBV DNA, HBV DNA polymerase, HCVRNA, anti HCV antibodies.
  18. Known active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with IV anti-infectives within 4 weeks of the Screening Visit or completion of oral anti-infectives within 2 weeks of the Screening Visit.
  19. History of deep space/tissue infection (e.g., fasciitis, abscess, osteomyelitis) within 52 weeks of the Screening Visit.
  20. History of serious infection or opportunistic infection in the last 2 years.
  21. Any neurological (congenital or acquired), vascular or systemic disorder that might affect any of the efficacy assessments, in particular, joint pain and swelling (e.g., Parkinson's disease, cerebral palsy, diabetic neuropathy).
  22. Currently active alcohol or drug abuse or history of alcohol or drug abuse (as determined by the investigator) within 52 weeks of the Screening Visit.
  23. Treatment with IV Gamma Globulin or the Prosorba® Column within 6 months of the Screening Visit.
  24. Treatment with IV or intramuscular corticosteroids.
  25. Previous treatment with a B cell modulating or cell depleting therapy.
  26. Intolerance or contraindications to IV glucocorticoids.
  27. AST or ALT > 3 times ULN.
  28. Hemoglobin < 8.0 g/dL.
  29. Levels of IgG < 5.0 g/L.
  30. Absolute neutrophil count < 1500/µL.
  31. Platelet count < 75000/µL.
  32. Participation in any previous clinical trial within 12 weeks of Screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01682512

  Hide Study Locations
Locations
United States, Alabama
Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
United States, Arizona
Boehringer Ingelheim Investigational Site
Glendale, Arizona, United States
Boehringer Ingelheim Investigational Site
Mesa, Arizona, United States
Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
United States, Arkansas
Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
United States, California
Boehringer Ingelheim Investigational Site
Covina, California, United States
Boehringer Ingelheim Investigational Site
El Cajon, California, United States
Boehringer Ingelheim Investigational Site
Lakewood, California, United States
Boehringer Ingelheim Investigational Site
Long Beach, California, United States
Boehringer Ingelheim Investigational Site
Sacramento, California, United States
Boehringer Ingelheim Investigational Site
San Diego, California, United States
Boehringer Ingelheim Investigational Site
San Leandro, California, United States
Boehringer Ingelheim Investigational Site
Santa Maria, California, United States
Boehringer Ingelheim Investigational Site
Thousand Oaks, California, United States
Boehringer Ingelheim Investigational Site
Upland, California, United States
United States, Connecticut
Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut, United States
United States, Florida
Boehringer Ingelheim Investigational Site
DeLand, Florida, United States
Boehringer Ingelheim Investigational Site
Miami, Florida, United States
Boehringer Ingelheim Investigational Site
Orlando, Florida, United States
Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida, United States
Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
Boehringer Ingelheim Investigational Site
Venice, Florida, United States
United States, Georgia
Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
United States, Idaho
Boehringer Ingelheim Investigational Site
Coeur D'Alene, Idaho, United States
Boehringer Ingelheim Investigational Site
Idaho Falls, Idaho, United States
United States, Illinois
Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
United States, Kansas
Boehringer Ingelheim Investigational Site
Overland Park, Kansas, United States
United States, Maryland
Boehringer Ingelheim Investigational Site
Columbia, Maryland, United States
Boehringer Ingelheim Investigational Site
Cumberland, Maryland, United States
Boehringer Ingelheim Investigational Site
Wheaton, Maryland, United States
United States, Massachusetts
Boehringer Ingelheim Investigational Site
Worcester, Massachusetts, United States
United States, Michigan
Boehringer Ingelheim Investigational Site
Grand Rapids, Michigan, United States
United States, Missouri
Boehringer Ingelheim Investigational Site
St. Louis, Missouri, United States
United States, Nebraska
Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
United States, New Jersey
Boehringer Ingelheim Investigational Site
Clifton, New Jersey, United States
Boehringer Ingelheim Investigational Site
Toms River, New Jersey, United States
United States, New Mexico
Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico, United States
United States, New York
Boehringer Ingelheim Investigational Site
Brooklyn, New York, United States
United States, North Carolina
Boehringer Ingelheim Investigational Site
Charlotte, North Carolina, United States
Boehringer Ingelheim Investigational Site
Greensboro, North Carolina, United States
United States, Ohio
Boehringer Ingelheim Investigational Site
Dayton, Ohio, United States
United States, Oklahoma
Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Boehringer Ingelheim Investigational Site
Duncansville, Pennsylvania, United States
United States, Tennessee
Boehringer Ingelheim Investigational Site
Memphis, Tennessee, United States
Boehringer Ingelheim Investigational Site
Nashville, Tennessee, United States
United States, Texas
Boehringer Ingelheim Investigational Site
Carrollton, Texas, United States
Boehringer Ingelheim Investigational Site
Corpus Christi, Texas, United States
Boehringer Ingelheim Investigational Site
Houston, Texas, United States
Boehringer Ingelheim Investigational Site
McKinney, Texas, United States
Boehringer Ingelheim Investigational Site
Webster, Texas, United States
United States, Virginia
Boehringer Ingelheim Investigational Site
Richmond, Virginia, United States
United States, Washington
Boehringer Ingelheim Investigational Site
Seattle, Washington, United States
Boehringer Ingelheim Investigational Site
Tacoma, Washington, United States
United States, West Virginia
Boehringer Ingelheim Investigational Site
Beckley, West Virginia, United States
Boehringer Ingelheim Investigational Site
Clarksburg, West Virginia, United States
Argentina
Boehringer Ingelheim Investigational Site
Buenos Aires, Argentina
Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
Boehringer Ingelheim Investigational Site
Ciudad Autonoma Buenos Aires, Argentina
Boehringer Ingelheim Investigational Site
Rosario, Argentina
Boehringer Ingelheim Investigational Site
San Miguel de Tucuman, Argentina
Belgium
Boehringer Ingelheim Investigational Site
Kortrijk, Belgium
Bulgaria
Boehringer Ingelheim Investigational Site
Plovdiv, Bulgaria
Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
Boehringer Ingelheim Investigational Site
Stara Zagora, Bulgaria
Canada, Ontario
Boehringer Ingelheim Investigational Site
Burlington, Ontario, Canada
Chile
Boehringer Ingelheim Investigational Site
Santiago, Chile
Germany
Boehringer Ingelheim Investigational Site
Berlin, Germany
Boehringer Ingelheim Investigational Site
Dresden, Germany
Boehringer Ingelheim Investigational Site
Magdeburg, Germany
Boehringer Ingelheim Investigational Site
Zerbst, Germany
Greece
Boehringer Ingelheim Investigational Site
Athens, Greece
Boehringer Ingelheim Investigational Site
Haidari, Greece
Boehringer Ingelheim Investigational Site
Larissa, Greece
Hungary
Boehringer Ingelheim Investigational Site
Budapest, Hungary
Ireland
Boehringer Ingelheim Investigational Site
Dublin, Ireland
Mexico
Boehringer Ingelheim Investigational Site
Cuauhtemoc, Mexico
Boehringer Ingelheim Investigational Site
Saltillo, Mexico
Boehringer Ingelheim Investigational Site
Tijuana, Mexico
Boehringer Ingelheim Investigational Site
Tlanepantla, Mexico
Netherlands
Boehringer Ingelheim Investigational Site
Amsterdam, Netherlands
Boehringer Ingelheim Investigational Site
Sneek, Netherlands
New Zealand
Boehringer Ingelheim Investigational Site
Timaru, New Zealand
Poland
Boehringer Ingelheim Investigational Site
Bialystok, Poland
Boehringer Ingelheim Investigational Site
Bydgoszcz, Poland
Boehringer Ingelheim Investigational Site
Elblag, Poland
Boehringer Ingelheim Investigational Site
Krakow, Poland
Boehringer Ingelheim Investigational Site
Warszawa, Poland
Boehringer Ingelheim Investigational Site
Wroclaw, Poland
Portugal
Boehringer Ingelheim Investigational Site
Almada, Portugal
Boehringer Ingelheim Investigational Site
Amadora, Portugal
Boehringer Ingelheim Investigational Site
Aveiro, Portugal
Boehringer Ingelheim Investigational Site
Lisboa, Portugal
Boehringer Ingelheim Investigational Site
Porto, Portugal
Boehringer Ingelheim Investigational Site
Viseu, Portugal
South Africa
Boehringer Ingelheim Investigational Site
Capetown, South Africa
Spain
Boehringer Ingelheim Investigational Site
Barcelona, Spain
Boehringer Ingelheim Investigational Site
Bilbao, Spain
Boehringer Ingelheim Investigational Site
La Coruña, Spain
Boehringer Ingelheim Investigational Site
Sabadell, Spain
Boehringer Ingelheim Investigational Site
Sevilla, Spain
Ukraine
Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
Boehringer Ingelheim Investigational Site
Lutsk, Ukraine
Boehringer Ingelheim Investigational Site
Lviv, Ukraine
Boehringer Ingelheim Investigational Site
Poltava, Ukraine
Boehringer Ingelheim Investigational Site
Vinnytsia, Ukraine
Boehringer Ingelheim Investigational Site
Zaporizhzhia, Ukraine
United Kingdom
Boehringer Ingelheim Investigational Site
London, United Kingdom
Boehringer Ingelheim Investigational Site
Newcastle upon Tyne, United Kingdom
Boehringer Ingelheim Investigational Site
Stoke on Trent, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01682512     History of Changes
Other Study ID Numbers: 1301.1
2011-002894-48 ( EudraCT Number: EudraCT )
Study First Received: August 10, 2012
Last Updated: March 2, 2017

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Rituximab
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents

ClinicalTrials.gov processed this record on March 28, 2017